Boulevard Bio Raises $65M for Immunology
Boulevard Bio raised $65M for precision immunology, showing continued investor interest in targeted immune therapies.
Biotech capital is still available for companies with focused scientific theses and strong specialist backing.
What happened
Boulevard Bio raised $65M for work in precision immunology. The New York-based startup is focused on immune-related therapeutic approaches.
The round gives the company fresh capital in a biotech market where investors have become more selective about new platform and therapeutics bets.
Why it matters
Precision immunology is attractive because immune-system biology sits behind many serious diseases, but broad immune interventions can be difficult to target safely and effectively.
Companies in this area are trying to make therapies more precise: better patient selection, better disease targeting and better clinical development paths.
The bigger picture
The biotech market is no longer rewarding every early science story equally. Rounds like Boulevard Bio’s show that capital is still flowing where investors see differentiated biology and a clear path toward therapeutic value.